137049-02-6

Basic information

• Product Name: 1,2-DIMETHYL-1H-IMIDAZOLE-4-SULFONYL CHLORIDE
• Synonyms: BUTTPARK 27\06-13;1,2-DIMETHYLIMIDAZOLE-4-SULFONYL CHLORIDE;1,2-DIMETHYLIMIDAZOLE-4-SULPHONYL CHLORIDE;1,2-DIMETHYL-1H-IMIDAZOLE-4-SULFONYL CHLORIDE;SALOR-INT L481165-1EA;1H-Imidazole-4-sulfonylchloride,1,2-dimethyl-(9CI);1,2-diMethyl-1H-iMidazol-4-sulfonyl chloride;1,2-dimethyl-4-imidazolesulfonyl chloride
• CAS NO: 137049-02-6
• Molecular Formula: C₅H₇ClN₂O₂S
• Molecular Weight: 194.64
• Product Categories: SULFONYLHALIDE
• Mol File: 137049-02-6.mol
• Article Data: 3

Chemical Properties

• Melting Point: 91 °C
• Boiling Point: 357.5 °C at 760 mmHg
• Flash Point: 170 °C
• Appearance: /
• Density: 1.52 g/cm³
• Vapor Pressure: 5.59E-05mmHg at 25°C
• Refractive Index: 1.605
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 1.18±0.70(Predicted)
• Stability: Moisture Sensitive, Hygroscopic
• CAS DataBase Reference: 1,2-DIMETHYL-1H-IMIDAZOLE-4-SULFONYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-DIMETHYL-1H-IMIDAZOLE-4-SULFONYL CHLORIDE(137049-02-6)
• EPA Substance Registry System: 1,2-DIMETHYL-1H-IMIDAZOLE-4-SULFONYL CHLORIDE(137049-02-6)

Safety Data

• Hazard Codes: Xi,C
• Statements: 34
• Safety Statements: 26-36/37/39
• RIDADR: 3261
• HazardClass: MOISTURE SENSITIVE, CORROSIVE
• Hazardous Substances Data: 137049-02-6(Hazardous Substances Data)

Usage

General Description

1,2-DIMETHYL-1H-IMIDAZOLE-4-SULFONYL CHLORIDE is a chemical compound with the molecular formula C5H8ClNO2S. It belongs to the class of sulfonamide compounds and is commonly used in organic synthesis and pharmaceutical research. This chemical is a reactive compound, with the chlorine atom being a vital site for reactions. It is primarily used to introduce the imidazole-4-sulfonyl chloride group, which is valuable in various applications such as the development of drugs, agrochemicals, and other biologically active compounds. Due to its reactivity, careful handling and appropriate safety precautions must be followed when working with this compound.

InChI:InChI=1/C5H7ClN2O2S/c1-4-7-5(3-8(4)2)11(6,9)10/h3H,1-2H3

Upstream product

• 1739-84-0 1,2-dimethyl-1H-imidazole 

Downstream Products

• 913358-49-3 (R)-2-{(3S,5R)-3-(3-chloro-phenyl)-4-[2-(1,2-dimethyl-1H-imidazole-4-sulfonylamino)-acetyl]-5-methyl-2-oxo-[1,4]diazepan-1-yl}-3-naphthalen-1-yl-propionamide 
• 1123301-29-0 1,2-dimethyl-1H-imidazole-4-sulfonic acid {2-[3'-(4-methoxymethyl-phenyl)-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl]-ethyl}-methyl-amide 
• 1123301-43-8 1,2-dimethyl-1H-imidazole-4-sulfonic acid {2-[3'-(2-fluoro-phenyl)-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl]-ethyl}-methyl-amide 
• 1156439-27-8 C₂₃H₂₄Cl₂FN₅O₃S 
• 1160508-25-7 5-((cyclohexylmethyl)((1-(1,2-dimethyl-1H-imidazol-5-ylsulfonyl)piperidin-4-yl)methyl)amino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one 
• 1136778-82-9 C₁₈H₂₆N₄O₄S 
• 1136473-56-7 C₂₀H₃₀N₄O₄S 
• 1136603-35-4 C₁₇H₂₈N₂O₄S 
• 1136424-99-1 C₂₀H₃₀N₄O₄S 
• 1136603-49-0 C₁₉H₂₈N₄O₄S 
• 1136427-57-0 C₁₈H₂₆N₄O₄S 

Relevant articles and documents

ALKYLAMINOPYRIDINE DERIVATIVE

The present invention relates to a compound that is useful for treatment of, for example, hypertension, arteriosclerosis, bulimia and obesity because of having an antagonistic action to a neuropeptide Y receptor and is represented by formula (I) [wherein R1 represents hydrogen, cyano, or the like; R represents a group represented by formula (II); X1 represents C1-4 lower alkylene or the like; X2 represents lower alkylene or the like; and Het represents a 5-membered heteroaromatic ring that has at least one nitrogen atom and, in addition, one or two hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms] or to a pharmaceutically acceptable salt thereof.

Imidazole compounds, processes for their preparation, pharmaceuticals based on these compounds and some intermediates

Imidazole compounds of the formula I STR1 in which R1 =alkyl, R2 and R3 =H, halogen or alkyl, X=OH or an amide radical having certain substituents, processes for their preparation and pharmaceuticals based on these compounds, in particular for the prophylaxis and treatment of circulatory disturbances, especially of disturbances of the microcirculation and of the disorders resulting therefrom, and some novel intermediates for the preparation of the compounds of the formula I, which are 1-methyl-, 1,2-dimethyl- and 1-ethyl-4-imidazolesulfonyl chloride.